Novo Nordisk's Diabetes, Weight Loss Drugs Under UK Scrutiny: Follows Suicidal Behavior Reports
Portfolio Pulse from Vandana Singh
The UK's Medicines and Healthcare Products Regulatory Agency (MHRA) is scrutinizing diabetes and weight loss drugs sold by Novo Nordisk, including Ozempic and Wegovy, following reports of suicidal behavior. The agency is also reviewing type 2 diabetes medications from AstraZeneca, Sanofi, and Eli Lilly. The EU's drugs watchdog recently raised a thyroid cancer safety signal for Novo Nordisk's drugs.
July 26, 2023 | 3:07 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
AstraZeneca's type 2 diabetes medication is also under review by the MHRA. This could potentially impact the company's sales and reputation.
The MHRA's review of AstraZeneca's diabetes medication could lead to potential regulatory actions, which could negatively impact the company's sales and reputation.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 60
NEGATIVE IMPACT
Eli Lilly's diabetes medication is under review by the MHRA. This could potentially impact the company's sales and reputation.
The MHRA's review of Eli Lilly's diabetes medication could lead to potential regulatory actions, which could negatively impact the company's sales and reputation.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 60
NEGATIVE IMPACT
Novo Nordisk's diabetes and weight loss drugs are under scrutiny by the UK's MHRA following reports of suicidal behavior. This could negatively impact the company's reputation and sales.
The scrutiny of Novo Nordisk's drugs by the MHRA could lead to potential regulatory actions, which could negatively impact the company's sales and reputation. The EU's drugs watchdog also recently raised a thyroid cancer safety signal for Novo Nordisk's drugs, adding to the potential negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Sanofi's diabetes medication is under review by the MHRA. This could potentially impact the company's sales and reputation.
The MHRA's review of Sanofi's diabetes medication could lead to potential regulatory actions, which could negatively impact the company's sales and reputation.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 60